Sangamo BioSciences | SGMO - مصاريف البيع والإدارة





مصاريف البيع والإدارة تغيير تاريخ
Alaunos Therapeutics USD 585K 84K 2025-09
Alnylam Pharmaceuticals USD 285.06M 22.47M 2025-12
Alterity Therapeutics Limited AUD 2.29M 649.1K 2023-06
Amgen USD 1.94B 237M 2025-12
Bayer EUR 4.05B 647M 2025-12
BioCryst Pharmaceuticals USD 95.78M 12.77M 2025-12
Biogen USD 545.2M 38.6M 2025-09
BioMarin Pharmaceutical USD 322.21M 98.79M 2025-12
Cipla INR 13.25B 101.8M 2025-12
Clal Biotechnology ILS 3.31M 513K 2022-12
Compugen USD 2.21M 120K 2025-12
CSL USD 1.23B 498M 2025-12
Gilead Sciences USD 1.78B 425M 2025-12
GlaxoSmithKline GBP 2.68B 518M 2025-12
Grifols EUR 320.45M 12.65M 2025-12
Ionis Pharmaceuticals USD 130M 43.43M 2025-12
J&J USD 6.75B 831M 2025-12
Karyopharm Therapeutics USD 27.19M 442K 2024-12
Merck USD 2.85B 215M 2025-12
Novartis USD 3.44B 128M 2025-12
Omeros USD 11.32M 2.48M 2024-09
Pfizer USD 4.08B 894M 2025-12
Roche Holding CHF 7.28B 3.99B 2025-12
Sangamo BioSciences USD 9.64M 1.83M 2024-06
Sanofi EUR 2.75B 455M 2025-12
Sarepta Therapeutics USD 105.38M 28.27M 2025-12
Tectonic Therapeutic USD 3.44M 1.52M 2025-12
Ultragenyx Pharmaceutical USD 89M 2.38M 2025-12
Vertex Pharmaceuticals USD 487M 41.9M 2025-12